Defining and managing high-risk acute myeloid leukemia (AML) in 2026.

Abstract excerpt

Acute myeloid leukemia (AML) remains a highly heterogeneous malignancy in which outcomes are particularly poor for patients classified as having high-risk disease. Traditionally, high-risk AML has been defined by adverse baseline genetic features, including complex cytogenetics, TP53 alterations, and mutations associated with secondary or therapy-related disease. However, this static, genetics-centered definition...

Topics

• Humans
• Leukemia, Myeloid, Acute
• Neoplasm, Residual
• Bridged Bicyclo Compounds, Heterocyclic
• Mutation
• Sulfonamides